| | Sequence identity (%)a | HA patternb | HA typec | COG groupd |
---|
Strains | | | Human(+Na) | Porcine | Human | Horse | | |
---|
A. naeslundii gsp 1 |
| 12104 | 100 | 1/8 | 1/4 | 1/2 | 1/8 | a | B |
| Pn-22-E | 97.6 | 1/32 | 1/16 | 1/4 | 1/8 | a | |
| Pn-6-N | 97.2 | 1/32 | 1/16 | 1/2 | 1/32 | a | |
| P-5-N | 93.8 | 1/16 | 1/4 | 0 | 0 | b | |
A. naeslundii gsp 2 |
| T14V | 100 | 1/16 | 0 | 0 | 0 | a | A |
| P-1-N | 99.3 | 1/16 | 0 | 0 | 0 | a | |
| P-1-K | 99.6 | 1/32 | 1/16 | 0 | 1/4 | b | |
| LY7 | 88.6 | 1/32 | 1/16 | 0 | 1/4 | b | F |
- aAmino acid sequence identity (%) within each genospecies as compared to strains 12104 or T14V, respectively.
- bHemagglutination (HA) of neuraminidase treated human and untreated porcine, human and horse red blood cells by reciprocal dilutions of bacterial cell suspensions. The lowest dilution with visible HA is given. 0 marks no agglutination even at the highest dilution.
- ca and b denotes the two hemagglutination patterns observed in each genospecies.
- dCoaggregation properties as defined by coaggregation groups (COG) A to F [27]